Insight Molecular Diagnostics
IMDX
30 hedge funds and large institutions have $14.3M invested in Insight Molecular Diagnostics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 21 closing their positions.
52.47% more ownership
Funds ownership: 2.79% → 55.25% (+52%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
32% less capital invested
Capital invested by funds: $21.1M → $14.3M (-$6.79M)
36% less funds holding
Funds holding: 47 → 30 (-17)
81% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$82.3K |
| 2 |
AIC
AWM Investment Company
New York
|
+$37.2K |
| 3 |
Renaissance Technologies
New York
|
+$19.8K |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.18K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$86.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$57.9K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$44.8K |
| 4 |
LPL Financial
San Diego,
California
|
-$29.3K |
| 5 |
VF
Virtu Financial
New York
|
-$15K |
IMDX Hedge Fund Activity: Q3 2023 in Review
30 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2023, worth a combined $14.3M — down 32% from $21.1M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of IMDX and 4 opened new positions — a net loss of 17 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $82.3K. The largest seller was Pura Vida Investments, cutting an estimated $86.1K.
- 30 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2023, down from 47 in Q2 2023.
- Funds reported $14.3M of Insight Molecular Diagnostics stock for Q3 2023, down 32% quarter-over-quarter.
- 4 funds opened new Insight Molecular Diagnostics positions in Q3 2023 and 21 closed out, a net change of -17 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2023 was Vanguard Group, an estimated $82.3K added.
- The largest Insight Molecular Diagnostics seller in Q3 2023 was Pura Vida Investments, an estimated $86.1K sold.
Based on aggregated 13F filings for Q3 2023.